Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Colby

Comparative Effectiveness of Treatments for Relapsed or Refractory Mantle Cell Lymphoma (R/R McL), Using Matching Adjusted Indirect Comparison

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Pcv116 - Discontinuation and Health Care Resource Utilisation in Non-Valvular Atrial Fibrillation Patients Treated With Apixaban or Warfarin in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Related publications

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Oral Azacytidine (Aza) and Romidepsin (R) Reveals Promising Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Improved Outcome for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Who Stop Ibrutinib +/− Rituximab for Reasons Other Than Progression of Disease

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Sintilimab for Relapsed/Refractory (R/R) Extranodal Nk/T Cell Lymphoma (Enktl): A Multicenter, Single-Arm, Phase 2 Trial (Orient-4)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy